A 15 amino acid peptide derived from human gastric juice, widely researched for its tissue-healing and cytoprotective properties.

A synthetic version of the naturally occurring peptide Thymosin Beta-4, studied for tissue repair, inflammation reduction, and vascular remodeling.

A long-acting GHRH analogue with a Drug Affinity Complex that extends its half-life dramatically, allowing weekly dosing for sustained GH elevation.

A highly selective GH secretagogue and ghrelin receptor agonist known for clean GH release without significant cortisol or prolactin stimulation.

A 29-amino acid truncated analogue of endogenous GHRH, FDA-approved for pediatric GHD and widely researched for anti-aging and body composition.

A potent GH secretagogue with strong ghrelin receptor activity, producing significant GH pulses with some cortisol and prolactin elevation.

One of the original GH secretagogue peptides, notable for strong hunger stimulation alongside robust GH release.

The most potent GH secretagogue peptide available, with additional direct cardiac and anti-fibrotic research applications.

A modified fragment of human growth hormone specifically targeting fat metabolism without the growth-promoting or diabetogenic effects of full GH.

A GLP-1 receptor agonist with FDA approval for type 2 diabetes and obesity, demonstrating unprecedented weight loss results in clinical trials.

A dual GIP/GLP-1 receptor agonist with FDA approval showing up to 22% weight loss — superior to semaglutide in head-to-head trials.

A triple GIP/GLP-1/glucagon receptor agonist in Phase III trials, showing over 24% weight loss — potentially the most powerful metabolic peptide in development.

A once-daily GLP-1 receptor agonist with FDA approval for T2D and obesity, the predecessor to semaglutide with strong clinical evidence.

The first GLP-1 receptor agonist approved by the FDA for T2D, derived from Gila monster venom with strong glucose-lowering and weight management effects.

A synthetic heptapeptide analogue of tuftsin with anxiolytic, nootropic, and immune-modulating properties developed in Russia.

A synthetic heptapeptide based on ACTH fragment with potent nootropic, neuroprotective, and stroke-recovery properties developed in Russia.

An extremely potent nootropic peptide (10 million times more potent than BDNF) that enhances synaptogenesis, with promising research in Alzheimer's models.

A naturally occurring neuropeptide that regulates sleep-wake cycles, stress response, and has shown longevity-associated effects in animal research.

A naturally occurring copper complex peptide with potent wound healing, anti-aging, and regenerative properties studied extensively for skin and tissue applications.

A synthetic alpha-MSH analogue with FDA-orphan drug approval for erythropoietic protoporphyria, producing skin darkening through melanin stimulation.

A cyclic alpha-MSH analogue with potent melanogenic, sexual arousal, and appetite-suppressing effects through broad melanocortin receptor activation.

A mitochondrial-derived peptide that regulates metabolic homeostasis, glucose uptake, and has shown remarkable longevity effects in animal studies.

A synthetic tetrapeptide based on Epithalamin with telomerase activation and antioxidant properties showing remarkable longevity effects in multiple animal species.

A mitochondria-derived peptide encoded in the 16S rRNA region with remarkable cytoprotective, anti-apoptotic, and longevity-associated properties.

A cardiolipin-targeted mitochondria-protective peptide showing remarkable results in heart failure, AMD, and mitochondrial disease research.

A 28-amino acid peptide derived from the thymus with potent immunomodulatory effects approved in multiple countries for hepatitis and cancer supportive care.

The only human cathelicidin antimicrobial peptide, with broad-spectrum antimicrobial activity, immunomodulation, and wound-healing properties.

Polypeptide extract from the thymus gland that broadly restores immune function and extends longevity in research.

FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder in premenopausal women, with off-label research in men.

An endogenous neuropeptide and master regulator of the HPG axis, GnRH release, and reproductive function with significant clinical research interest.

The endogenous hypothalamic hormone that regulates the HPG axis through pulsatile GnRH receptor signaling, used in fertility and hormonal research.

Engineered D-retro-inverso peptide that selectively induces apoptosis in senescent cells, reversing aging hallmarks in mice.

Endogenous heptapeptide that counterbalances Angiotensin II — cardioprotective, anti-fibrotic, and vasodilatory.